Stage I-II endometrial adenocarcinoma evolution of therapeutic paradigms: The role of surgery and adjuvant radiation

International Journal of Gynecological Cancer

Volumn 12, Issue 3, 2002, Pages 237-249

  Look, K ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

Adjuvant radiation; Endometrial adenocarcinoma

Indexed keywords

BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER GRADING; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; HIGH RISK PATIENT; HUMAN; HYSTERECTOMY; MEDLINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SALPINGOOOPHORECTOMY; SURVIVAL RATE;

ADENOCARCINOMA; CLINICAL TRIALS; COMBINED MODALITY THERAPY; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; HYSTERECTOMY; NEOPLASM STAGING; POSTOPERATIVE CARE; PREOPERATIVE CARE; RADIOTHERAPY, ADJUVANT;

EID: 0036071228     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2002.01119.x     Document Type: Review

References (99)

1. Endometrial cancer
2. The continuing epidemics of obesity and diabetes in the United States
3. Cancer statistics, 2001
4. Epidemiology of cervical and endometrial cancer
5. Postoperative radiotherapy for endometrial carcinoma. Stage I. Wide variation in referral patterns but no effect on long-term survival in a retropsective study in the southeast Netherlands
6. Adenocarcinoma of the endometrium: Survival comparisons of patients with and without pelvic node sampling
7. Endometrial Cancer Study Groups Pelvic lymphadenectomy in high risk endometrial cancer
8. Improved outcome in patients treated with postoperative radiation therapy for pathologic stage I/II endometrial cancer
9. Pelvic node metastasis in endometrial cancer with no myometrial invasion
10. Evaluation of different surgical approaches to the treatment of endometrial cancer at FIGO, Stage I
11. Clincal Stage I Adenocarcinoma of the endometrium - Analysis of recurrences and the potential benefit of staging lymphadenectomy
12. Excellent long-term survival and absence of vaginal recurrences in 332 patients with low risk stage I enodmetrial adenocarcinoma treated with hysterectomy and vaginal brachytherapy without formal staging lymph node sampling: Report of a prospective trial
13. Lymph node sampling and survival in endometrial cancer
14. Society of Gynecologic Oncologists (SGO) outcomes task force study of endometrial cancer initial experience
15. The use of adjuvant radiation therapy by members of the Society of Gynecologic Oncologists
16. A phase III randomized study of surgery versus surgery plus adjunctive radiation therapy in intermediate risk endometrial adenocarcinoma
17. Randomized trial of surgery and postoperative radiation therapy versus surgery alone for patients with stage I endometrial carcinoma
18. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma. Clinical and histopathologic study of 540 patients
19. Carcinoma of the endometrium: Radiation followed immediately by operation
20. A prospective trial comparing hysterectomy, hysterectomy plus vaginal radium and uterine radium plus hysterectomy in stage I endometrial carcinoma
21. The role of preoperative brachytherapy as an adjunct to surgery and post-operative radiotherapy in the treatment of Stage I endometrial carcinoma
22. Comparison of clinical and surgical staging in patients with endometrial carcinoma
23. Uterine papillary serous carcinoma. A highly malignant form of endometrial adenocarcinoma
24. Clear cell carcinoma of the endometrium
25. Surgical staging in endometrial cancer: Clinical-pathologic findings of a prospective study
26. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study
27. Risk factors and recurrent patterns in stage I endometrial adenocarcinoma
28. Annual report on the results of treatment in gynecologic cancer
29. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A gynecologic oncology group study
30. Endometrial cancer
31. Elevation of serum CA125 in carinomas of the falllopian tube, endometrium and endocervix
32. Predictive value of preoperative serum CA125 levels in clincally localized and advanced endometrial carcinoma
33. Value of preoperative CA125 level in the management of uterine cancer and prediction of clinical outcome
34. Myometrial invasion by endometrial carcinoma: Songographic asssessment
35. Depth of myometrial invasion in endometrial cancer: Pre-operative assessment by transvaginal ultrasonography
36. Assessment of myometrial infiltration and preoperative staging by transvaginal ultrasound in patients with endometrial carcinoma
37. Transvaginal sonography vs hysteroscopy in the preoperative staging of endometrial carcinoma
38. Magnetic resonance imaging determination of myometrial invasion in endometrial cancer
39. Magnetic resonance imaging in stage I endometrial carcinoma
40. Clinical stage I endometrial carcinoma: Pitfalls in pre-opeative assessment with MR imaging
41. Pre-operative staging of endometrial carcinoma: Diagnostic effect of T2-weighted fastspin echo
42. Detection of deep myometrial invasion in endometrial carcinoma: Comparison of transvaginal ultrasound, CT, MRI
43. Tumor size in endometrial cancer: A prognostic factor for lymph node metastases
44. Intraoperative evaluation of depth of myometrial invasion in stage I endometrial adenocarcinoma
45. Prognostic significance of gross myometrial invasion with endometrial cancer
46. Reliability of frozen section examination in stage I endometrial adenocarcinoma
47. Accuracy of frozen section diagnosis at surgery in clinical stge I and II endometrial carcinoma
48. Local staging of endometrial carcinoma: Comparison of transvaginal and intraoperative sonography and gross visual inspection
49. Low risk corpus cancer: Is lymphadenectomy or radiotherapy necessary?
50. A comparison of treatment strategies for endometrial adenocarcinoma: Analysis of financial impact
51. Surgery without radiotherapy for primary treatment of endometrial cancer
52. Stage I corpus cancer: Is teletherapy necessary?
53. Pelvic and paraaortic lymphadenectomy for surgical staging of endometrial cancer: Morbidity and mortality
54. Selective pelvic and periaortic lymphadenectomy does not increase morbidity in surgical staging of endometrial carcinoma
55. Morbidity of lymph node sampling in cancer of the uterine corpus and cervix
56. Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II
57. Hysterectomy with extended surgical staging and radiotherapy versus hysterectomy alone and radiotherapy in stage I endometrial cancer: A comparison of complication rates
58. Enteric morbidity of postoperative plevic external beam and brachytherapy for uterine cancer
59. Pathologic models to predict outcome for women with endometrial adenocarcinoma. The importance of the distinction between surgical stage and clinical stage - A Gynecologic Oncology Group study
60. Determinants of survival of surgically staged patients with endometrial carcinoma histologically confined to the uterus: Implications for therapy
61. The prognostic significance of lymph-vascular space invasion in stage I endometrial cancer
62. Endometrial carcinoma influence of prognostic factors on radiation management
63. The prognostic significance of vascular invasion by endometrial carcinoma
64. Practice guidelines
65. Predictors of distant recurrence in clinical stage I or II endometrial carcinoma treated by combination surgical and radiation therapy
66. Benefit of external irradiation in pathologic stage I endometrial carcinoma: A prospective clinical trial of 605 pts who received postoperative vaginal irradiation and additional pelvic irradiation in the presence of unfavorable prognostic factors
67. Good outcome associated with a standardized treatment protocol using selective postoperative radiation in patients with clinical stage I adenocarcinoma of the endometrium
68. The role of adjuvant radiotherapy In carcinoma of the endometrium - Results in 550 patients with pathologic stage I disease
69. Adjuvant vaginal high-dose rate afterloading alone in endometrial carcinoma. Patterns of relapse and side effects following low-dose therapy
70. Treatment results in women with clinical stage I and pathologic stage II endometrial carcinoma
71. Outpatient vaginal cuff brachytherapy for endometrial cancer
72. Para-aortic lymph node radiotherapy in cancer of the uterine corpus
73. Look KFIGO Stage IIIC endometrial carcinoma with metastases confined to pelvic lymph nodes. Analysis of treatment outcomes, prognostic variables and failure patterns following adjuvant radiation therapy
74. The effect of post-surgical therapy on stage III Endometrial cancer
75. Endometrial cancer with para-aortic adenopathy. Patterns of failure and opportunities for cure
76. Long term survival of intermediate risk endometrial cancer (Stage IG3, IC, II) treated with full lymphadenectomy and brachytherapy without teletherapy
77. Postoperative vaginal vault brachytherapy for nodenegative stage II (occult) endometrial carcinoma
78. High-dose-rate postoperative vaginal cuff irradiation alone for stage IB and IC endometrial cancer
79. Patterns of failure in endometrial carcinoma stage IB grade 3 and IC patients with postoperative vaginal vault brachytherapy
80. Local recurrence in high-risk node-negative Stage I endometrial carcinoma treated with postoperative vaginal vault brachytherapy
81. A prospective trial of postoperative vaginal radium/cesium for grade 1-2 less than 50% myometrial invasion and pelvic radiation therapy for grade 3 or deep invasion in surgical stage 1 endometrial adenocarcinoma
82. Pelvic control following external beam radiation for surgical stage I endometrial adenocarcinoma
83. Benefit of adjuvant radiotherapy in surgically staged stage I-II endometrial carcinoma
84. Postoperative radiation therapy for surgically staged endometrial cancer. Impact of time factors (overall treatment time and surgery-to-radiation interval) on outcome
85. Which prognostic factos influence the outcome of patients with surgically staged endometrial cancer treated with adjuvant radiation
86. High-dose rate brachytherapy alone posthysterectomy for endometrial cancer
87. Postoperative radiotherapy and surgery in stage I endometrial carcinoma: A 10-year experience
88. External pelvic radiation in stage IC endometrial carcinoma
89. Surgery and postoperative radiation therapy in stage II endometrial carcinoma
90. Is there a role for a brachytherapy vaginal cuff boost in the adjuvant management of patients with uterine-confined endometrial cancer?
91. Conservative management of endometrial carcinoma with myometrial invasion after surgical staging
92. Prognostic factors and treatment outcome for patients with locally recurrent endometrial cancer
93. The salvage of recurrent endometrial carcinoma in the vagina and pelvis
94. Endometrial carcinoma - Relative effectiveness of adjuvant irradiation vs therapy reserved for relapse
95. The morbidity of surgery and adjuvant radiotherapy in the management of endometrial carcinoma
96. Impact of improved irradiation technique, age and lymph node sampling on the severe complication rate of surgically staged endometrial cancer patients: A multivariate analysis
97. Analysis of complications in patients with endometrial carcinoma receiving adjuvant irradiation
98. Cost effectiveness of treatment of early endometrial cancer